Printer Friendly

Biotinylated probe isolation of targeted gene region improves detection of T790M epidermal growth factor receptor mutation via peptide nucleic acid-enriched real-time PCR.

Non-small-cell lung cancer (NSCLC) [3] patients harboring EGFR4 (epidermal growth factor receptor)activating mutations are initially responsive to small-molecule tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib; however, almost all of these patients develop drug resistance after prolonged treatment (1). For example, T790M, an acquired mutation that renders NSCLC patients resistant to gefitinib or erlotinib, is found in approximately 50% of tumors from patients who have acquired resistance to these kinase inhibitors (1-4). The presence of the T790M mutation in a primary lung tumor is considered clinically important and is a contraindication to the use of small-molecule TKIs for treatment (1-4). Similarly, the emergence of the T790M mutation in plasma from patients treated with TKIs is an indication of developing resistance (5).

Methods have been developed to detect the T790M mutation, with detection limits ranging from 1 mutant allele in 10 wild-type alleles to 1 in 2000 (6-9). These methods include a peptide nucleic acid (PNA)clamping method (10, 11). PNAs have been widely used in PCR reactions as a "clamp" to inhibit the amplification of wild-type DNA and thereby enrich for mutant alleles (12). Detection limits for this method currently range from 1 mutant allele in 100 wild-type alleles to 1 in 1000 (10, 11). There is an increasing need, however, to further improve the detection of EGFR T790M because DNA with the T790M mutation can be initially present as a minor clone in a cancer that subsequently becomes drug resistant (13). It would be important to be able to screen tumors from NSCLC patients for the existence of the T790M mutation before they undergo TKI treatment, because patients with evidence of T790M may derive an even briefer benefit from EGFR TKI therapy (14). Furthermore, the detection of EGFR T790M in a lung cancer before any therapym could change the treatment from gefitinib to an irreversible EGFR inhibitor that is effective against the T790M mutation (15).

We demonstrate that biotinylated probe-based purification of a target from genomic DNA produces a major improvement in PNA-PCR-based mutation detection by increasing the sensitivity for detecting the mutation to at least 1 mutant allele in 40 000 wild-type alleles.

Reference human male genomic DNA was purchased from Promega and used as the wild-type DNA in dilution experiments with DNA containing the T790M mutation (H1975 cell line). DNA was extracted from cell lines with the QIAamp DNA Blood Maxi Kit (Qiagen). Primers and probes were synthesized by Integrated DNA Technologies. DNA was quantified with a NanoDrop spectrophotometer (Thermo Scientific).

Real-time PCR reactions were performed in a 25-[micro]L volume in the presence of a dye that binds to the DNA minor grove (LCGreen [Plus.sup.+]; Idaho Technology) and with 20 ng genomic DNA prepared directly from cell lines. To quantify copies of EGFR exon 20, we serially diluted genomic DNA with human male genomic DNA calibrator. The final concentrations of the other PCR reagents were as follows: 1 x GoTaq Flexi Buffer (Promega), 0.63 U of GoTaq Flexi DNA polymerase (Promega), 0.2 mmol/L of each deoxynucleoside triphosphate, 0.2 [micro]mol/L forward primer (5' -GCTGGGCATCTGCCTCA-3'), 0.2 [micro]mol/L reverse primer (5'-CAGGAGGCAGCCGAAGG-3'), 2.5 mmol/L Mg[Cl.sub.2], and 0.1 x LC-Green [Plus.sup.+]. The size of the PCR amplicon is 67 bp. The PCR cycling was performed on a Cepheid SmartCycler[TM] machine as follows: 95 [degrees]C for 120 s and 50 cycles of 95 [degrees]C for 15 s and 60 [degrees]C for 30 s (fluorescence reading on), followed by DNA melting from 60 [degrees]C to 95 [degrees]C at a temperature-ramping rate of 0.2 [degrees]C/s. Genomic DNA containing at least 106 copies of EGFR exon 20 molecules were digested in a 480-[micro]L reaction volume containing 1 x NEBuffer 2 (New England Biolabs), BSA (0.1 g/L), 100 U each of RsaI, EcoRI, BamHI, and EcoRV (all 4 restriction enzymes from New England Biolabs). The reaction was incubated at 37 [degrees]C for 3 h and then purified in an Ultracel YM-30 Microcon column (Millipore). DNA was eluted in 30 [micro]L water. To enrich for EGFR exon 20, we added a 5'-biotinylated probe (biotin-Spacer 18-GCCTGCTGGGCATCTGCCTCACCTCCACCG; synthesized by Integrated DNA Technologies) to the purified digested genomic DNA and diluted the probe to a final concentration of 33 nmol/L with 6X SSPE Buffer (American Bioanalytical) in a 45-[micro]L volume. The mixture was denatured at 100 [degrees]C for 2 min in a PCR thermocycler and then quickly cooled on ice for 5 min. The hybridization was then performed in a thermocycler for 16 h at 58 [degrees]C. The hybridization mixture was then purified with an Ultracel YM-30 Microcon column and eluted in 40 [micro]L water. We washed 10 [micro]L Dynabeads M-270 Streptavidin (Invitrogen) 3 times with 1 x binding and washing buffer (5 mmol/L Tris HCL, pH 7.5, 0.5 mmol/L EDTA, and 1 mol/L NaCl) and resuspended the beads in 40 [micro]L of 2X binding and washing buffer. The 40-u L hybridization mixture of purified probe and target was captured by mixing it with the 40 [micro]L of processed Dynabeads and incubating the mixture on a shaker for 1h at room temperature. The beads were washed 3 times with 1 X binding and washing buffer supplemented with 1 mL/L Tween 20, twice with 1 X binding and washing buffer, and once with water. Finally, the beads were resuspended in 15 u L water, denatured at 95 [degrees]C for 2 min, and placed immediately on DynaMag magnets (Invitrogen). The suspension was recovered for further analysis.

The PNA-clamp reaction components were similar to those for the LCGreen dye quantification of EGFR exon 20 described above, except for the use of a locked nucleic acid-modified TaqMan probe and PNA clamp, as previously reported (11), instead of the LCGreen dye. The final concentrations of the TaqMan probe and PNA were both 0.2 [micro]mol/L. Approximately 100 ng of genomic DNA or, alternatively, 2 [micro]L purified target were used for T790M detection. The PCR cycling conditions were 95 [degrees]C for 120 s and 70 cycles of 95 [degrees]C for 15 s and 60 [degrees]C for 30 s (fluorescence reading on). PCR products were purified with exonuclease I (New England Biolabs) and shrimp alkaline phosphatase (USB/Affymetrix) according to the manufacturers' instructions. We then used primer 5'-40T-GCTGGGCATCTGCCTCA-3' (Integrated DNA Technologies) to sequence the purified product by the Sanger method. Precautions were taken to minimize carryover contamination, and PCR tubes were prepared and uncapped in a negative-flow hood. All experiments were repeated from starting material at least 4 independent times.

As shown in Fig. 1A in the Data Supplement that accompanies the online version of this brief communication at http://www.clinchem.org/content/vol57/ issue5, genomic DNA is first digested by a restriction endonuclease (RsaI in this case) into fragments, one of which contains the entire target region between 2 closely spaced restriction sites. The duplexes containing the hybridized probe and EGFR exon 20 are bound to the streptavidin-coated magnetic beads and washed. EGFR exon 20 single-stranded DNA is released from the beads by brief heat denaturation. A PNA clamp-based real-time PCR with a TaqMan probe containing a locked nucleic acid matching the T790M mutation [as described by Miyazawa et al. (11)] is then used to quantify the T790M mutation (see Fig. 1B in the online Data Supplement). With the biotinylated probe, we achieved an enrichment in EGFR exon 20 of at least 1000-fold relative to other genomic DNA fragments. This enrichment estimate is based on the amount of isolated product and results obtained with input genomic DNA in a TaqMan-based real-time PCR targeting the GAPDH (glyceraldehyde-3-phosphate dehydrogenase) gene (data not shown). This result translates into a recovery efficiency for EGFR exon 20 of approximately 20%30% relative to the input genomic DNA.

We diluted genomic DNA from the H1975 cell line with the T790M mutation by 1000- to 40 000-fold with wild-type DNA. To enable the detection of low-level mutations, we used genomic DNA containing approximately 106 copies of EGFR exon 20 for isolation via the biotin probe. To evaluate the reproducibility of the biotin-isolation process and to enable a fair comparison of the mutation-detection limit of PNA clamp-based PCR, we measured the copy number of EGFR exon 20 several times in independent experiments before performing the PNA-PCR amplification. LCGreen-based real-time PCR analyses of EGFR exon 20 fragments containing the T790M mutation isolated from dilutions into wild-type DNA (1000- to 40 000-fold dilution) demonstrated equal numbers of copies of EGFR exon 20 (see Fig. 2 in the online Data Supplement). The LCGreen dye does not discriminate between wild-type and mutant sequences and therefore can be used to quantify EGFR exon 20 copy number for all samples. The real-time PCR calibration curve was established with a serially diluted human control genomic DNA of known concentration, as we have previously described (9).

We used equal numbers of EGFR exon 20 copies isolated from wild-type DNA to test serially diluted T790M mutations via PNA probe-enriched real-time PCR. When genomic DNA is used as the starting material (Fig. 1A), the detection limit is 1 T790M allele in 1000 wild-type alleles, a result in agreement with Miyazawa et al. (11). The inability to distinguish lower concentrations of the mutation is due to increased background signals (false positives) generated by the wild-type DNA (Fig. 1A). In contrast, the approach involving isolating the biotin target can clearly detect T790M mutations at concentrations as low as 1 mutant allele in 40 000 wild-type alleles (Fig. 1B), because the wild-type samples are reproducibly not generating false-positive signals.

To better understand the origin of the background signals from wild-type samples when starting from genomic DNA, we used genomic DNA and biotin-isolated starting DNA and sequenced the PNA-PCR product from the 1:1000 (i.e., 1 mutant allele among 1000 wild-type alleles) dilution and wild-type samples. Wild-type DNA from genomic DNA produces false-positive T790M signals (see Fig. 3 in the online Data Supplement), possibly because of polymerase misincorporations in early PCR cycles; however, wild-type DNA from biotin-isolated DNA does not show the T790M OT mutation at this position. Using PNAPCR may require several PCR cycles to accumulate enough copies of the target molecules for efficient binding by the PNA probe, which may allow polymerase misincorporations to occur in wild-type DNA-samples when starting from genomic DNA, but not when biotin probes are used.

[FIGURE 1 OMITTED]

Target purification via biotinylated probes has previously been used to increase the number of starting target copies before constant denaturant capillary electrophoresis or restriction fragment length polymorphism analysis (16, 17). The present work demonstrates that for methods such as PNA-PCR that operate by enriching the mutation during PCR amplification, biotin probe isolation of the target further improves PCR-based mutation detection by avoiding PCR errors at early PCR cycles. Because of the relatively large amount of starting genomic DNA required for the present procedure (approximately 5 [micro]g), this approach is intended primarily for screening tumor tissue or cell lines for rare mutations. The present improvement should also be applicable for detecting other PNA clamp-enriched mutations or to alternative methods that enrich mutations during the PCR, such as restriction endonuclease-mediated selective PCR (18, 19) or coamplification at lower denaturation temperature PCR (20, 21).

Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; and (c) final approval of the published article.

Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the Disclosures of Potential Conflict of Interest form. Potential conflicts of interest:

Employment or Leadership: None declared.

Consultant or Advisory Role: P.A. Janne, Pfizer, AstraZeneca, Roche, Genentech, and Boehringer Ingelheim.

Stock Ownership: P.A. Janne, Gatekeeper Pharmaceuticals.

Honoraria: None declared.

Research Funding: G.M. Makrigiorgos, NIH grant CA-138280; P.A. Janne, NIH grants CA-135257 and CA-090578.

Expert Testimony: None declared.

Other Remuneration: P.A. Janne, Genzyme.

Role of Sponsor: The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, or preparation or approval of manuscript.

Disclaimer: The contents of this report are the responsibility of the authors and do not necessarily represent the official views of the NIH.

References

(1.) Janne PA. Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours. Lung Cancer 2008;60(Suppl 2):S3-9.

(2.) Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.

(3.) Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92.

(4.) Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008;14:2895-9.

(5.) Kuang Y, Rogers A, Yeap BY, Wang L, Makrigiorgos M, Vetrand K, et al. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res 2009; 15:2630-6.

(6.) Thomas RK, Nickerson E, Simons JF, Janne PA, Tengs T, Yuza Y, et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med 2006;12:852-5.

(7.) Inukai M, Toyooka S, Ito S, Asano H, Ichihara S, Soh J, et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 2006; 66:7854-8.

(8.) Vikis H, Sato M, James M, Wang D, Wang Y, Wang M, et al. EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. Cancer Res 2007;67:4665-70.

(9.) Li J, Wang L, Janne PA, Makrigiorgos GM. Coamplification at lower denaturation temperature-PCR increases mutation-detection selectivity of TaqMan-based real-time PCR. Clin Chem 2009; 55:748-56.

(10.) Beau-Faller M, Legrain M, Voegeli AC, Guerin E, Lavaux T, Ruppert AM, et al. Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping. Br J Cancer 2009;100:985-92.

(11.) Miyazawa H, Tanaka T, Nagai Y, Matsuoka M, Sutani A, Udagawa K, et al. Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation. Cancer Sci 2008;99:595-600.

(12.) Pellestor F, Paulasova P, Hamamah S. Peptide nucleic acids (PNAs) as diagnostic devices for genetic and cytogenetic analysis. Curr Pharm Des 2008;14:2439-44.

(13.) Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borras AM, Gale CM, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 2006;116:2695-706.

(14.) Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359:366-77.

(15.) Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, McNamara K, et al. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 2007;12:81-93.

(16.) Bielas JH, Loeb KR, Rubin BP, True LD, Loeb LA. Human cancers express a mutator phenotype. Proc Natl Acad Sci USA 2006;103:18238-42.

(17.) Li-Sucholeiki XC, Thilly WG. A sensitive scanning technology for low frequency nuclear point mutations in human genomic DNA. Nucleic Acids Res 2000;28:E44.

(18.) Fuery CJ, Impey HL, Roberts NJ, Applegate TL, Ward RL, Hawkins NJ, et al. Detection of rare mutant alleles by restriction endonuclease-mediated selective-PCR: assay design and optimization. Clin Chem 2000;46:620-4.

(19.) Amicarelli G, Shehi E, Makrigiorgos GM, Adlerstein D. FLAG assay as a novel method for realtime signal generation during PCR: application to detection and genotyping of KRAS codon 12 mutations. Nucleic Acids Res 2007;35:e131.

(20.) Li J, Wang L, Mamon H, Kulke MH, Berbeco R, Makrigiorgos GM. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med 2008; 14:579-84.

(21.) Milbury CA, Li J, Makrigiorgos GM. Ice-COLD-PCR enables rapid amplification and robust enrichment for low-abundance unknown DNA mutations. Nucleic Acids Res 2011;39:e2.

Jin Li, [1] Pasi A. Janne, [2] and G. Mike Makrigiorgos [1] *

[1] Department of Radiation Oncology, Dana-Farber/ Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA; [2] Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; * address correspondence to this author at: Dana-Farber/Brigham and Women's Cancer Center, Brigham and Women's Hospital, Level L2, Radiation Therapy, 75 Francis St., Boston, MA 02115. E-mail mmakrigiorgos@partners.org.

[3] Nonstandard abbreviations: NSCLC, non-small-cell lung cancer; TKI, tyrosine kinase inhibitor; PNA, peptide nucleic acid.

[4] Human genes: EGFR, epidermal growth factor receptor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

Previously published online at DOI: 10.1373/clinchem.2010.157784
COPYRIGHT 2011 American Association for Clinical Chemistry, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Brief Communication
Author:Li, Jin; Janne, Pasi A.; Makrigiorgos, G. Mike
Publication:Clinical Chemistry
Date:May 1, 2011
Words:2862
Previous Article:Prevalence of blood doping in samples collected from elite track and field athletes.
Next Article:A liquid chromatography--tandem mass spectrometry method for salivary testosterone with adult male reference interval determination.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters